Atlas Trials

A Phase Ib/II Study of BM230 in Combination With PD-1 Inhibitor for HER2-related Advanced Solid Tumors

Clinical trial NCT07698587 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07698587
Sponsor
Suzhou Biomissile Pharmaceuticals Co., Ltd.
Status
NOT_YET_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Solid Tumor
Start date
2026-07-01
Primary completion
2029-12-01
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.